enGene Therapeutics Inc. (ENGN)
Data as of , from SEC Form 4 filings.
See up to 3 months of ENGN. The 7-day demo opens the 1M and 3M ranges and puts ENGN on your watchlist.
Start 7-day demoLatest ENGN insider trades
About enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
- SAINT-LAURENT
- 82
- 2023
- XNAS
ENGN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 5,102 | $10K |
ENGN insider transactions (Form 4)
4229 Form 4 filings on record, the earliest from Oct 1, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| William Grossman - Officer | Open-market purchase | Common Shares | 5,102 | $1.97 | $10K | |
| Philip Astley-Sparke | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Gerald A. Brunk | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Richard M. Glickman | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| William Grossman - Officer | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| William Grossman - Officer | Grant or award | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
 Paul J. Hastings | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
 Michael Thomas Heffernan | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Wouter Joustra | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Lota S. Zoth | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Anthony Tzeyew Cheung - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
 Lee Giguere - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
 Alexander Julian Nichols - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
 D. Ryan Daws - Officer | Grant or award | Stock Option (Right to Buy) | 220,000 | $0.00 | - | |
| Ronald Harold Wilfred Cooper - Officer | Grant or award | Stock Option (Right to Buy) | 801,000 | $0.00 | - | |
| Joan Connolly - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
| Matthew Ross Boyd - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
| Jill Buck - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
| Hussein Sweiti - Officer | Grant or award | Stock Option (Right to Buy) | 600,000 | $0.00 | - | |
| Matthew Ross Boyd - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Jill Buck - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| William Grossman | Grant or award | Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| Michael Thomas Heffernan | Grant or award | Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| Philip Astley-Sparke | Grant or award | Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| Lota S. Zoth | Grant or award | Stock Option (Right to Buy) | 22,500 | $0.00 | - | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 561,797 | $8.90 | $5.00M | |
| Anthony Tzeyew Cheung - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Joan Connolly - Officer | Grant or award | Stock Option (Right to Buy) | 210,000 | $0.00 | - | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 2,750 | $7.17 | $20K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 5,050 | $7.69 | $39K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 400 | $8.30 | $3K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 9,620 | $9.09 | $87K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 38,396 | $5.94 | $228K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 3,243 | $6.38 | $21K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 341,332 | $6.34 | $2.16M | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 35,279 | $6.44 | $227K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 10,153 | $6.37 | $65K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 5,769 | $6.48 | $37K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 5,997 | $6.54 | $39K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 11,844 | $6.55 | $78K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 800 | $6.60 | $5K | |
| Ronald Harold Wilfred Cooper - Officer | Open-market purchase | Common Shares | 10,000 | $5.70 | $57K |
ENGN insider trading FAQ
What is the latest insider trade for ENGN?
enGene Therapeutics Inc. (ENGN) had 1 insider filing in the last 90 days, with the most recent on 2026-09-24. The full record for ENGN runs to 29 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ENGN stock?
1 insider purchase of ENGN was filed in the last 90 days, totaling $10K.
How many insiders are selling ENGN stock?
No insider sales of ENGN were filed in the last 90 days.
Where can I see ENGN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ENGN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - William Grossman view on EDGAR
- - Philip Astley-Sparke view on EDGAR
- - Gerald A. Brunk view on EDGAR
- - Richard M. Glickman view on EDGAR
- - William Grossman view on EDGAR
- - Paul J. Hastings view on EDGAR
- - Michael Thomas Heffernan view on EDGAR
- - Wouter Joustra view on EDGAR
- - Lota S. Zoth view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where ENGN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ENGN with a 7-day demo
- ENGN on your watchlist
- Every ENGN Form 4 filing on record
- Up to 3 months of ENGN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
